专利检索_ 作用于NADH或NADPH的氧化还原酶专利检索_ 作用于NADH或NADPH的氧化还原酶专利检索查询

子分类：

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
1	METHODS FOR SINGLE CHAIN VARIABLE REGION ENOX2 ANTIBODIES FOR CANCER DETECTION AND DIAGNOSIS	US15205656	2016-07-08	US20170030918A1	2017-02-02	D. James Morre; Brandon Eugene Hostetler; James Jinpal Kim
Cancers of different cellular or tissue origins express different ENOX2 cancer isoforms or combinations of isoforms and shed these proteins into the circulation. Herein are disclosed methods both for cancer detection and diagnosis of particular origin, based on the patterns and molecular weights of the isoforms which allow the identification of the cell type and or tissue of origin of the neoplasm. Relative ENOX2 amounts are proportional to tumor burden and provide a reliable measure of response to therapy and disease progression. Also provided is the amino acid sequence to which the scFv antibodies bind as the molecular basis for the specificity of the test.
2	Methods for single chain variable region ENOX2 antibodies for cancer detection and diagnosis	US15205656	2016-07-08	US09804166B2	2017-10-31	D. James Morre; Brandon Eugene Hostetler; James Jinpal Kim
Cancers of different cellular or tissue origins express different ENOX2 cancer isoforms or combinations of isoforms and shed these proteins into the circulation. Herein are disclosed methods both for cancer detection and diagnosis of particular origin, based on the patterns and molecular weights of the isoforms which allow the identification of the cell type and or tissue of origin of the neoplasm. Relative ENOX2 amounts are proportional to tumor burden and provide a reliable measure of response to therapy and disease progression. Also provided is the amino acid sequence to which the scFv antibodies bind as the molecular basis for the specificity of the test.
3	Methods and compositions for targeted two-dimensional western blot analysis for early cancer detection and cancer diagnosis up to ten years in advance of clinical symptoms of malignant disease	US15434982	2017-02-16	US09804165B1	2017-10-31	D. James Morre
The present invention includes methods for detecting benign to malignant transformation of a cancer in a subject, comprising the steps of: collecting a sample from the subject prior to electrophoretic protein separation; activating electrophoretically separated ENOX2 transcript variants with an ENOX2 electron donor; and detecting the presence of the one or more activated ENOX2 transcript variants using a pan-ENOX2 detectable binding reagent, wherein the presence of one or more activated ENOX2 transcript variants in the sample is indicative of the malignant transformation of the cancer, whereby a 10 to 100 fold increase in detection sensitivity is obtained for the one or more activated ENOX2 transcript variants when compared to an equivalent non-activated ENOX2 transcript variant.
4	TARGETED TWO-DIMENSIONAL WESTERN BLOT ANALYSIS FOR EARLY CANCER DETECTION	EP16180364.8	2016-07-20	EP3252473A1	2017-12-06	MORRE, D. James
The present invention includes methods for detecting benign to malignant transformation of a cancer in a subject, comprising the steps of: collecting a sample from the subject prior to electrophoretic protein separation; activating electrophoretically separated ENOX2 isoforms with an ENOX2 electron donor; and detecting the presence of the one or more activated ENOX2 isoforms using a pan-ENOX2 detectable binding reagent (comprising an scFv), wherein the presence of one or more activated ENOX2 isoforms in the sample is indicative of the malignant transformation of the cancer, whereby a 10 to 100 fold increase in detection sensitivity is obtained for the one or more activated ENOX2 isoforms when compared to an equivalent non-activated ENOX2 isoform. A corresponding calibrated quantitation method furthermore involving a western-blot is also disclosed. Here the blot is exposed to a reducing substrate for ENOX2.
5	METHODS AND COMPOSITIONS FOR SINGLE CHAIN VARIABLE REGION ENOX2 ANTIBODIES FOR CANCER DETECTION AND DIAGNOSIS	US15653241	2017-07-18	US20170343555A1	2017-11-30	D. James Morre; Brandon Eugene Hostetler; James Jinpal Kim
Cancers of different cellular or tissue origins express different ENOX2 cancer isoforms or combinations of isoforms and shed these proteins into the circulation. Herein are disclosed methods both for cancer detection and diagnosis of particular origin, based on the patterns and molecular weights of the isoforms which allow the identification of the cell type and or tissue of origin of the neoplasm. Relative ENOX2 amounts are proportional to tumor burden and provide a reliable measure of response to therapy and disease progression. Also provided is the amino acid sequence to which the scFv antibodies bind as the molecular basis for the specificity of the test.
6	Methods and compositions for targeted two-dimensional western blot analysis for early cancer detection and cancer diagnosis up to ten years in advance of clinical symptoms of malignant disease	US15169205	2016-05-31	US09612243B1	2017-04-04	D. James Morre
The present invention includes methods for detecting benign to malignant transformation of a cancer in a subject, comprising the steps of: collecting a sample from the subject prior to electrophoretic protein separation; activating electrophoretically separated ENOX2 transcript variants with an ENOX2 electron donor; and detecting the presence of the one or more activated ENOX2 transcript variants using a pan-ENOX2 detectable binding reagent, wherein the presence of one or more activated ENOX2 transcript variants in the sample is indicative of the malignant transformation of the cancer, whereby a 10 to 100 fold increase in detection sensitivity is obtained for the one or more activated ENOX2 transcript variants when compared to an equivalent non-activated ENOX2 transcript variant.
7	悪性疾患の臨床症状より最大10年前に早期がんを検出及びがんを診断するための標的化2次元ウエスタンブロット分析の方法及び組成物	JP2016119555	2016-06-16	JP2017215305A	2017-12-07	モッレディー.ジェームス
【課題】対象におけるがんの良性から悪性へのトランスフォーメーションを検出する方法を提供する。【解決手段】電気泳動タンパク質分離の前に、対象から試料を採取するステップ、電気泳動で分離されたENOX2転写物バリアントをENOX2電子供与体で活性化するステップ、及び全てのENOX2を検出可能な結合試薬を用いて、1又は2以上の活性化ENOX2転写物バリアントの存在を検出するステップを含み、前記試料における1又は2以上の活性化ENOX2転写物バリアントの存在が、がんの悪性トランスフォーメーションを示し、それにより、同等の非活性化ENOX2転写物バリアントと比較したとき、前記1又は2以上の活性化ENOX2転写物バリアントについて、検出感度の10〜100倍の増大が得られる、方法。【選択図】なし
8	Aberrant mitochondrial dna, related fusion transcripts and translation products, as well as the hybridization probe	JP2012501093	2010-03-29	JP2012521745A	2012-09-20	クライン，ダニエル; クリード，ジェニファー; ダクボ，ガブリエル; パー，ライアン; ハーボトル，アンドリュー; レガリー，ブライアン; ロビンソン，ケリー
本発明は、癌を予測し、診断しおよび／またはモニタリングするのに有用な新規のミトコンドリア融合転写物および親突然変異化ｍｔＤＮＡ分子を提供する。それと相補的なハイブリダイゼーションプローブも、本発明の方法に用いるために提供される。
9	ABERRANT MITOCHONDRIAL DNA, ASSOCIATED FUSION TRANSCRIPTS AND TRANSLATION PRODUCTS AND HYBRIDIZATION PROBES THEREFOR	EP10761136.0	2010-03-29	EP2411522B1	2017-09-06	PARR, Ryan; DAKUBO, Gabriel; HARBOTTLE, Andrew; REGULY, Brian; CREED, Jennifer; ROBINSON, Kerry; KLEIN, Daniel

10	ABERRANT MITOCHONDRIAL DNA, ASSOCIATED FUSION TRANSCRIPTS AND TRANSLATION PRODUCTS AND HYBRIDIZATION PROBES THEREFOR	EP10761136	2010-03-29	EP2411522A4	2013-01-02	PARR RYAN; DAKUBO GABRIEL; HARBOTTLE ANDREW; REGULY BRIAN; CREED JENNIFER; ROBINSON KERRY; KLEIN DANIEL

11	ABERRANT MITOCHONDRIAL DNA, ASSOCIATED FUSION TRANSCRIPTS AND TRANSLATION PRODUCTS AND HYBRIDIZATION PROBES THEREFOR	EP10761136.0	2010-03-29	EP2411522A1	2012-02-01	PARR, Ryan; DAKUBO, Gabriel; HARBOTTLE, Andrew; REGULY, Brian; CREED, Jennifer; ROBINSON, Kerry; KLEIN, Daniel
The present invention provides novel mitochondrial fusion transcripts, the parent mutated mtDNA molecules, and the resulting translation products (proteins) for predicting, diagnosing and/or monitoring cancer. Hybridization probes complementary thereto for use in the methods of the invention are also provided.
12	이상 미토콘드리아 디엔에이, 관련된 융합 전사물 및 번역 산물 및 이에 대한 하이브리드화 탐침	KR1020117025261	2010-03-29	KR101720555B1	2017-03-29	파르,라이언; 다쿠보,가브리엘; 하보틀,앤드류; 레귤리,브라이언; 크리드,제니퍼; 로빈슨,케리; 클라인,다니엘
본발명은암을예견, 진단및/또는모니터하기위한신규의미토콘드리아융합전사물, 모돌연변이된 mtDNA 분자, 및생성되는번역산물(단백질)을제공한다. 본발명의방법에사용하기위한상기에상보성인하이브리드화탐침을또한제공한다.
13	이상 미토콘드리아 디엔에이, 관련된 융합 전사물 및 번역 산물 및 이에 대한 하이브리드화 탐침	KR1020117025261	2010-03-29	KR1020140014360A	2014-02-06	파르,라이언; 다쿠보,가브리엘; 하보틀,앤드류; 레귤리,브라이언; 크리드,제니퍼; 로빈슨,케리; 클라인,다니엘
본 발명은 암을 예견, 진단 및/또는 모니터하기 위한 신규의 미토콘드리아 융합 전사물, 모 돌연변이된 mtDNA 분자, 및 생성되는 번역 산물(단백질)을 제공한다. 본 발명의 방법에 사용하기 위한 상기에 상보성인 하이브리드화 탐침을 또한 제공한다.
14	METHODS AND COMPOSITIONS FOR SINGLE CHAIN VARIABLE REGION ENOX2 ANTIBODIES FOR CANCER DETECTION AND DIAGNOSIS	PCT/US2012059141	2012-10-05	WO2013052926A3	2013-05-30	MORRE D JAMES; HOSTETLER BRANDON EUGENE; KIM JAMES JINPAL
[0076] All neoplastic cells express one or more members of a unique family of cell surface ubiquinone (NADH) oxidase proteins with protein disulfide-thiol interchange activity (ECTO-NOX proteins) that are characteristically inhibited by quinone site inhibitors with anti-cancer activity and a common amino acid sequence disclosed herein that allows for cancer-specific antibody recognition as well as for detection of certain critical reference proteins that provide loading controls. Cancers of different cellular or tissue origins express different ENOX2 cancer isoforms or combinations of isoforms and shed these proteins into the circulation. Herein are disclosed methods both for cancer detection and diagnosis of particular origin, based on the patterns and molecular weights of the isoforms which allow the identification of the cell type and or tissue of origin of the neoplasm. Relative ENOX2 amounts are proportional to tumor burden and provide a reliable measure of response to therapy and disease progression. Also provided is the amino acid sequence to which the scFv antibodies bind as the molecular basis for the specificity of the test.

该功能需要专业版企业版VIP权限，您可以：